Nkarta/$NKTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Nkarta
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
- Ticker
- $NKTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 106
- Headquarters
- South San Francisco, United States
- Website
- www.nkartatx.com
Nkarta Metrics
BasicAdvanced
$211M
-
-$1.58
0.98
-
Price and volume
Market cap
$211M
Beta
0.98
52-week high
$3.72
52-week low
$1.70
Average daily volume
550K
Financial strength
Current ratio
7.981
Quick ratio
7.846
Long term debt to equity
0.267
Total debt to equity
0.297
Profitability
EBITDA (TTM)
-113.441
Management effectiveness
Return on assets (TTM)
-19.57%
Return on equity (TTM)
-38.76%
Valuation
Price to book
0.85
Price to tangible book (TTM)
0.85
Price to free cash flow (TTM)
-2.331
Free cash flow yield (TTM)
-42.90%
Free cash flow per share (TTM)
-1.265
Growth
Earnings per share change (TTM)
6.81%
3-year earnings per share growth (CAGR)
-14.82%
What the Analysts think about Nkarta
Analyst ratings (Buy, Hold, Sell) for Nkarta stock.
Analyst projections of the future price of Nkarta stock.
Nkarta Financial Performance
Revenues and expenses
Nkarta Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Nkarta
Fund name | Fund size | $NKTX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.